Your browser is no longer supported. Please, upgrade your browser.
Settings
GTH Genetron Holdings Limited daily Stock Chart
GTH [NASD]
Genetron Holdings Limited
Index- P/E- EPS (ttm)-4.56 Insider Own- Shs Outstand80.42M Perf Week10.14%
Market Cap1.05B Forward P/E- EPS next Y- Insider Trans- Shs Float3.20M Perf Month-
Income-94.10M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales41.60M P/S25.21 EPS this Y12.00% Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.01 P/C1310.85 EPS next 5Y- ROE- 52W Range11.09 - 17.71 Perf YTD-18.50%
Dividend- P/FCF- EPS past 5Y- ROI-90.80% 52W High-26.37% Beta-
Dividend %- Quick Ratio0.70 Sales past 5Y- Gross Margin44.40% 52W Low17.58% ATR1.38
Employees663 Current Ratio0.80 Sales Q/Q15.30% Oper. Margin- RSI (14)- Volatility7.56% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.48 Prev Close13.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.71M Price13.04
Recom- SMA20-2.83% SMA50-2.83% SMA200-2.83% Volume846,476 Change-6.19%
Jun-30-20 08:55AM  
Jun-19-20 08:45AM  
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.